Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business clinical trial failure

EyePoint DURAVYU Phase 3 Trial Fails

Analysis based on 33 articles · First reported Aug 21, 2026 · Last updated Sep 03, 2026

Sentiment
-80
Attention
4
Articles
33
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

EyePoint's stock collapsed by about 67% on the trial failure, erasing roughly 70% of shareholder value. The event also triggered multiple securities investigations, potentially leading to litigation costs and reputational damage for the company.

Biotechnology Pharmaceuticals

On August 17, 2026, EyePoint Pharmaceuticals announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU (vorolanib intravitreal insert) in wet age-related macular degeneration. The trial failed to meet its prespecified primary endpoint of change in best-corrected visual acuity versus on-label aflibercept (Regeneron's Eylea) in the full dataset. The company highlighted favorable secondary results, including a 42% reduction in treatment burden, and an ad hoc analysis excluding a 4% asymmetric patient cohort, but the primary endpoint failure stood. Following the announcement, EyePoint's stock plummeted nearly 67%, wiping out roughly 70% of market value in a single session. Several law firms, including Pomerantz LLP, Levi & Korsinsky, and Kessler Topaz Meltzer & Check, launched investigations into potential securities fraud, focusing on whether EyePoint adequately disclosed trial risks and the asymmetric patient cohort despite repeatedly describing the program as 'derisked' on earnings calls from Q4 2024 through Q1 2026.

100 EyePoint Pharmaceuticals disclosed missed endpoint
80 Levi & Korsinsky commenced investigation EyePoint Pharmaceuticals
80 Pomerantz LLP launched investigation EyePoint Pharmaceuticals
70 Jay S. Duker made confident statements
stock
EyePoint is the central company whose lead drug candidate DURAVYU failed its Phase 3 trial, causing a massive stock decline and triggering securities investigations.
Importance 100.0 Sentiment -90.0
priv
Pomerantz LLP launched an investigation into potential securities fraud by EyePoint, representing investors who suffered losses.
Importance 60.0 Sentiment 0.0
priv
Levi & Korsinsky initiated an investigation into EyePoint's disclosures, focusing on the company's 'derisked' claims and the asymmetric patient cohort.
Importance 60.0 Sentiment 0.0
priv
Kessler Topaz Meltzer & Check is investigating EyePoint for potential securities law violations and encouraging affected investors to contact the firm.
Importance 60.0 Sentiment 0.0
per
Jay S. Duker, CEO of EyePoint, made optimistic statements about DURAVYU's 'derisked' potential prior to the trial failure, which are now under scrutiny in the investigations.
Importance 50.0 Sentiment -70.0
stock
Regeneron's Eylea was the comparator in the LUGANO trial; the failure of DURAVYU may reinforce Eylea's market position.
Importance 40.0 Sentiment 20.0
per
Joseph E. Levi is a partner at Levi & Korsinsky who is actively soliciting EyePoint investors for the investigation.
Importance 30.0 Sentiment 0.0
per
Danielle Peyton is the contact at Pomerantz LLP for investors seeking to join the investigation.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.